Amit G Singal1,2, Nabihah Tayob3, Anand Mehta4, Jorge A Marrero1,2, Hashem El-Serag5, Qingchun Jin3, Cristian Saenz de Viteri6, Austin Fobar6, Neehar D Parikh6. 1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 2. Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 3. Department of Biostatistics, Dana Farber Cancer Center, Boston, Massachusetts, USA. 4. Department of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. 5. Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA. 6. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
BACKGROUND AND AIMS: Most patients with HCC are diagnosed at a late stage, highlighting the need for more accurate surveillance tests. Although biomarkers for HCC early detection have promising data in Phase 2 case-control studies, evaluation in cohort studies is critical prior to adoption in practice. We leveraged a prospective cohort of patients with Child-Pugh A or B cirrhosis who were followed until incident HCC, liver transplantation, death, or loss to follow-up. We used a prospective specimen collection, retrospective, blinded evaluation design for biomarker evaluation of GALAD (gender × age × log alpha-fetoprotein [AFP] × des-gamma-carboxy prothrombin), longitudinal GALAD, and the HCC Early Detection Screening (HES) algorithm-compared to AFP-using patient-level sensitivity and screening-level specificity. APPROACH AND RESULTS: Of 397 patients with cirrhosis, 42 developed HCC (57.1% early stage) over a median of 2.0 years. Longitudinal GALAD had the highest c-statistic for HCC detection (0.85; 95% CI, 0.77-0.92) compared to single-time point GALAD (0.79; 95% CI, 0.71-0.87), AFP (0.77; 95% CI, 0.69-0.85), and HES (0.76; 95% CI, 0.67-0.83). When specificity was fixed at 90%, the sensitivity for HCC of single-time point and longitudinal GALAD was 54.8% and 66.7%, respectively, compared to 40.5% for AFP. Sensitivity for HCC detection was higher when restricted to patients with biomarker assessment within 6 months prior to HCC diagnosis, with the highest sensitivities observed for single-time point GALAD (72.0%) and longitudinal GALAD (64.0%), respectively. Sensitivity of single-time point and longitudinal GALAD for early-stage HCC was 53.8% and 69.2%, respectively. CONCLUSION: GALAD demonstrated high sensitivity for HCC detection in a cohort of patients with cirrhosis. Validation of these results is warranted in large Phase 3 data sets.
BACKGROUND AND AIMS: Most patients with HCC are diagnosed at a late stage, highlighting the need for more accurate surveillance tests. Although biomarkers for HCC early detection have promising data in Phase 2 case-control studies, evaluation in cohort studies is critical prior to adoption in practice. We leveraged a prospective cohort of patients with Child-Pugh A or B cirrhosis who were followed until incident HCC, liver transplantation, death, or loss to follow-up. We used a prospective specimen collection, retrospective, blinded evaluation design for biomarker evaluation of GALAD (gender × age × log alpha-fetoprotein [AFP] × des-gamma-carboxy prothrombin), longitudinal GALAD, and the HCC Early Detection Screening (HES) algorithm-compared to AFP-using patient-level sensitivity and screening-level specificity. APPROACH AND RESULTS: Of 397 patients with cirrhosis, 42 developed HCC (57.1% early stage) over a median of 2.0 years. Longitudinal GALAD had the highest c-statistic for HCC detection (0.85; 95% CI, 0.77-0.92) compared to single-time point GALAD (0.79; 95% CI, 0.71-0.87), AFP (0.77; 95% CI, 0.69-0.85), and HES (0.76; 95% CI, 0.67-0.83). When specificity was fixed at 90%, the sensitivity for HCC of single-time point and longitudinal GALAD was 54.8% and 66.7%, respectively, compared to 40.5% for AFP. Sensitivity for HCC detection was higher when restricted to patients with biomarker assessment within 6 months prior to HCC diagnosis, with the highest sensitivities observed for single-time point GALAD (72.0%) and longitudinal GALAD (64.0%), respectively. Sensitivity of single-time point and longitudinal GALAD for early-stage HCC was 53.8% and 69.2%, respectively. CONCLUSION: GALAD demonstrated high sensitivity for HCC detection in a cohort of patients with cirrhosis. Validation of these results is warranted in large Phase 3 data sets.
Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506
Authors: Paolo Del Poggio; Stefano Olmi; Francesca Ciccarese; Mariella Di Marco; Gian Ludovico Rapaccini; Luisa Benvegnù; Franco Borzio; Fabio Farinati; Marco Zoli; Edoardo Giovanni Giannini; Eugenio Caturelli; Maria Chiaramonte; Franco Trevisani Journal: Clin Gastroenterol Hepatol Date: 2014-02-26 Impact factor: 11.382
Authors: Amit G Singal; Mahendra Nehra; Beverley Adams-Huet; Adam C Yopp; Jasmin A Tiro; Jorge A Marrero; Anna S Lok; William M Lee Journal: Am J Gastroenterol Date: 2013-01-22 Impact factor: 10.864
Authors: Ju Dong Yang; Benyam D Addissie; Kristin C Mara; William S Harmsen; Jianliang Dai; Ning Zhang; Nicha Wongjarupong; Hawa M Ali; Hamdi A Ali; Fatima A Hassan; Sravanthi Lavu; Jessica L Cvinar; Nasra H Giama; Catherine D Moser; Katsuyuki Miyabe; Loretta K Allotey; Alicia Algeciras-Schimnich; J Paul Theobald; Melissa M Ward; Mindie H Nguyen; Alex S Befeler; K Rajender Reddy; Myron Schwartz; Denise M Harnois; Hiroyuki Yamada; Sudhir Srivastava; Jo Ann Rinaudo; Gregory J Gores; Ziding Feng; Jorge A Marrero; Lewis R Roberts Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-11-21 Impact factor: 4.090
Authors: Nicole E Rich; Binu V John; Neehar D Parikh; Ian Rowe; Neil Mehta; Gaurav Khatri; Smitha M Thomas; Munazza Anis; Mishal Mendiratta-Lala; Christopher Hernandez; Mobolaji Odewole; Latha T Sundaram; Venkata R Konjeti; Shishir Shetty; Tahir Shah; Hao Zhu; Adam C Yopp; Yujin Hoshida; Francis Y Yao; Jorge A Marrero; Amit G Singal Journal: Hepatology Date: 2020-10-25 Impact factor: 17.425
Authors: Nabihah Tayob; Douglas A Corley; Israel Christie; Lucy Almers; Ahmed K Rahal; Peter Richardson; Donna L White; Jessica Davila; Fasiha Kanwal; Hashem B El-Serag Journal: Clin Gastroenterol Hepatol Date: 2020-08-05 Impact factor: 13.576
Authors: Bojan Losic; Amanda J Craig; Carlos Villacorta-Martin; Sebastiao N Martins-Filho; Nicholas Akers; Xintong Chen; Mehmet E Ahsen; Johann von Felden; Ismail Labgaa; Delia DʹAvola; Kimaada Allette; Sergio A Lira; Glaucia C Furtado; Teresa Garcia-Lezana; Paula Restrepo; Ashley Stueck; Stephen C Ward; Maria I Fiel; Spiros P Hiotis; Ganesh Gunasekaran; Daniela Sia; Eric E Schadt; Robert Sebra; Myron Schwartz; Josep M Llovet; Swan Thung; Gustavo Stolovitzky; Augusto Villanueva Journal: Nat Commun Date: 2020-01-15 Impact factor: 14.919
Authors: Yucel Aydin; Ali Riza Koksal; Paul Thevenot; Srinivas Chava; Zahra Heidari; Dong Lin; Tyler Sandow; Krzysztof Moroz; Mansour A Parsi; John Scott; Ari Cohen; Srikanta Dash Journal: J Hepatocell Carcinoma Date: 2021-12-08
Authors: Amit G Singal; Benjamin Haaland; Neehar D Parikh; A Burak Ozbay; Carol Kirshner; Shubham Chakankar; Kyle Porter; Jagpreet Chhatwal; Turgay Ayer Journal: Hepatol Commun Date: 2022-08-09